|
August 4-6, 2009
(August 4 pre-conference workshop*, August 5-6 main conference)
从发现科学、基础研究、到应用领域，癌症临床治疗试验，及其技术创新
癌症治疗药的失败率相较于其它治疗领域为高，主要是因为缺乏人类癌症的临床前期模型、在门诊展现效力的挑战、以及癌症药物临床试验设计的复杂性。链接发现科学、临床科学、以及临床试验设计间之差距，藉以改良从临床前期到临床阶段之转译(translation)是提升癌症药物批准率的重要因素。在这个会议中，将介绍许多癌症药物的最新发展现况，许多企业正在探索填补这个创新的缺口，其中包括肝癌细胞研究之新发现、对癌有效之分子标靶药物等，都展现出莫大之可能性。此外，首次从法规及FDA的立场来探讨在癌症药物发展策略中，扮演重要角色之生物标靶的发展及其诊断结果的实际案例，另外为了癌症临床试验所进行之患者分类，阶层化的方法等将一并介绍。
Why You Should Attend:
- Listen to the latest information from companies developing therapeutics based on cancer stem cell research
- Learn about the regulatory pathway and FDA position on biomarkers and companion diagnostics for cancer
- Evaluate data emerging from exciting cancer targets/pathways and cancer epigenetic studies
- Hear the latest clinical results of combinations of molecular targeted cancer agents
Confirmed Speakers and Sessions
(As of March 13, 2009)
Pre-Conference Workshop
Biomarkers and Companion Diagnostics for Cancer Therapy
- Towia A. Libermann, Associate Professor of Medicine, Beth Israel Deaconess Medical Center and Director, BIDMC Genomics and Proteomics Center
- Murray O. Robinson, Ph.D., Senior Vice President, Oncology, AVEO Pharmaceuticals, Inc.
- Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.
- Nicholas C. Dracopoli, Ph.D., Vice President, Biomarkers, Centocor R&D, Johnson & Johnson
- John C Bloom, Ph.D., Executive Director, Diagnostic and Experimental Medicine, Eli Lilly and Company
- Richard A. Bender, M.D., Vice President and Chief Medical Officer, Agendia BV
Main Conference
Understanding and Exploiting the Role of Cancer Stem Cells in Drug Development
- Timothy Hoey, Ph.D., Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.
- Jeff Jackson, Ph.D., Director, Cancer Stem Cell DPU, Oncology R&D, GlaxoSmithKline
- Jenny P. Mather, M.D., Ph.D., Senior Vice President, Cancer Stem Cell Research, MacroGenics, Inc. West
- Ivan Bergstein, M.D., CEO, Stemline Therapeutics, Inc.
- Chia Portera, M.D., Ph.D., Assistant Medical Director, Exploratory Clinical Development, Genentech BioOncology
- Lyuba Varticovski, Staff Clinician, National Cancer Institute
New Approaches for Targeting Cancer
- Sandra S. McAllister, Ph.D., Postdoctoral Associate, Robert Weinberg Laboratory, Whitehead Institute for Biomedical Research
- Jon Oliner, M.D., Ph.D., Scientific Director, Oncology Research, Amgen, Inc.
- Patrick Trojer, Ph.D., Senior Scientist, Constellation Pharmaceuticals
- Hao Zhu, M.D., Post-Doctoral Fellow, Department of Hematology/Oncology, The George Q. Daley Laboratory, Dana Farber Cancer Institute and Children's Hospital of Boston
- Heidi Greulich, Ph.D., Instructor, Dana Farber Cancer Institute and Visiting Scientist, The Broad Institute of MIT and Harvard
Point-Counterpoint Debate and Discussion: Innovation Starvation in Oncology Drug Development: Implications for R&D Strategies
- John Herrmann, Ph.D., Executive Director, Search & Evaluation (Oncology), EMD Serono (U.S. Division of Merck Serono)
- Daniel S. Pereira, Ph.D., Vice President, Head of Research, Pharma Research Toronto, Hoffmann-La Roche Ltd., Canada
Combination Cancer Therapies and Multi-Targeting Strategies for Novel Therapeutics
- Kenneth C. Anderson, M.D, Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute and Kraft Family Professor of Medicine, Harvard Medical School
- Helen Chen, M.D., Associate Branch Chief, Cancer Therapy Evaluation Program, National Cancer Institute
- Asha Das, M.D., Medical Director, BioOncology, Genentech
- Daniel Passeri, President and CEO, Curis, Inc.
Strategic Discussion Group: Are Targeted Therapies Better than Non-Targeted Therapies?
- William N. Hait, M.D., Ph.D., Senior Vice President, Worldwide Head Oncology/Hematology R&D, Ortho Biotech Oncology R&D, The Johnson & Johnson Family of Companies
Translational Strategies for Cancer Drug Development
- Herbert A. Fritsche, Ph.D., Professor and Chief of Clinical Chemistry, The University of Texas M. D. Anderson Cancer Center
- Daniel B. Tumas, Ph.D., Director, Drug Safety Evaluation, Gilead Sciences, Inc.
- Kevin Webster, Ph.D., Executive Director, Cancer and Infection Drug Discovery, AstraZeneca R&D (Invited)
- Chris H. Takimoto, M.D., Ph.D., Senior Director, Translational Medicine, Ortho Biotech Oncology R&D/Centocor R&D, Inc
Scientific Advisory Board
Helen Chen, M.D., Associate Branch Chief, Cancer Therapy Evaluation Program, National Cancer Institute
Kevin P. Foley, Ph.D., Director of In Vivo Pharmacology, Synta Pharmaceuticals Corp.
William Hait, M.D., Ph.D., Senior Vice President, Worldwide Head, Oncology/Hematology R&D, Ortho Biotech Oncology - A J&J Co.
John Herrmann, Ph.D., Executive Director, Search & Evaluation (Oncology), EMD Serono (U.S. Division of Merck Serono)
Julia Y. Ljubimova, M.D., Ph.D., Director of Drug Delivery and Nanomedicine, Department of Neurosurgery, Cedars-Sinai Medical Center
John Newcomb, Ph.D., Director, Research, Hematology/Oncology Research, Amgen, Inc.
Lyuba Varticovski, Staff Clinician, National Cancer Institute
|
